Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 98
- Registration Number
- NCT05183035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Alliance for Childhood Diseases dba Cure 4 The Kids Foundation, Las Vegas, Nevada, United States
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 39
- Registration Number
- NCT05182385
- Locations
- 🇩🇪
Charité - Campus Benjamin Franklin, Berlin, Germany
🇩🇪University Hospital of Frankfurt (Main), Frankfurt (Main), Hessen, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Chen Suning
- Target Recruit Count
- 188
- Registration Number
- NCT05177731
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Conditions
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05168930
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸South Shore Hospital, South Weymouth, Massachusetts, United States
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 218
- Registration Number
- NCT05168202
- Locations
- 🇺🇸
Local Institution - 0001, Houston, Texas, United States
🇦🇺Local Institution - 0027, Wollongong, New South Wales, Australia
🇦🇺Local Institution - 0006, Clayton, Victoria, Australia
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05157971
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05155709
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇺🇸Oregon Health Sciences University ., Portland, Oregon, United States
🇺🇸Texas Oncology Sammons Cancer Center Sammons Cancer Center (SC), Dallas, Texas, United States
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 44
- Registration Number
- NCT05144243
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 232253, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University /ID# 233704, Wenzhou, Zhejiang, China
🇨🇳Duplicate_The Affiliated Hospital of Guizhou Medical University /ID# 232465, Guiyang, China
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT05107856
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT05105841
- Locations
- 🇯🇵
National Cancer Center Hospital /ID# 232449, Chuo-ku, Tokyo, Japan
🇯🇵University Hospital Kyoto Prefectural University of Medicine /ID# 239883, Kyoto-shi, Kyoto, Japan
🇯🇵Tohoku University Hospital /ID# 238433, Sendai-shi, Miyagi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.